debate right now over whether low-dose versions of Mevacor and Pravachol should be sold OTC

August 2000

There's lots of debate right now over whether low-dose versions of Mevacor and Pravachol should be sold OTC.

The FDA is holding meetings...and considering a switch.

The Amer Pharmaceutical Assoc strongly supports it.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote